Matinas Biopharma Holdings, Inc. (MTNB) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Matinas Biopharma second quarter 2023 financial results conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at that time, please press star 1 on your telephone keypad. If anyone has difficulty hearing the conference, please press star 0 for operator assistance. As a reminder, this conference is being recorded. I would now like to turn the conference over to Jody Kane. Please go ahead. This is Jody Kane with LHA. Thank you for participating in today's call. Joining me from Martinez Biopharma are Jerry Jabbour, Chief Executive Officer, Dr. Terry Matkiewicz, Chief Development Officer, and Keith Kaczynski, Chief Financial Officer. We also have Dr. Terry Ferguson, Chief Medical Officer, available to answer questions during the Q&A session. I'd like to remind listeners that remarks made During this call, may state management's future intentions, hopes, beliefs, expectations, or projections. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements are made pursuant to the safe harbor provision of the federal securities laws. These forward-looking statements are based on Matinus Biopharma's current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Matinus Biopharma files with the Securities and Exchange Commission. These documents are available in the investor section of the company's website and on sec.gov. Furthermore, the content of this con...